Global Acute Ischemic Stroke Therapeutics Market 2017-2021

Publisher Name :
Date: 09-Aug-2017
No. of pages: 84
Price : Single User: US $ 3500  US $ 2500 Corporate User: US $ 5000  US $ 4000
Inquire Before Buying
Avail $1000 Discount on this report till 31 August 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

About Acute Ischemic Stroke Therapeutics

AIS is a chronic condition characterized by the sudden loss of blood supply to a part of the brain, thus causing subsequent loss of neurological function. AIS is caused by thrombotic or embolic obstruction of the cerebral artery and is more common than hemorrhagic stroke. The global AIS therapeutics market is expected to register a low single digit market growth during the forecast period. The marginal growth rate is attributed to the lack of approved drugs in this area, the presence of alternative therapies, extensive use of generics, and unmet needs for anticoagulant reversal agents.

The analysts forecast global acute ischemic stroke therapeutics market to grow at a CAGR of 2.11% during the period 2017-2021.

Covered in this report

This report covers the present scenario and the growth prospects of the global acute ischemic stroke therapeutics market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs from various drug classes.

The market is divided into the following segments based on geography:

Americas

APAC

EMEA

This report, Global Acute Ischemic Stroke Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

Bayer

Boehringer Ingelheim

F. Hoffmann-La Roche

Sanofi

Other prominent vendors

Biogen

Daiichi Sankyo

Pfizer

Market driver

Increasing adoption of NOACs

For a full, detailed list, view our report

Market challenge

Unmet needs for anticoagulant reversal agents

For a full, detailed list, view our report

Market trend

TBI, a value-addition in AIS research

For a full, detailed list, view our report

Key questions answered in this report

What will the market size be in 2021 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

Avail $1000 Discount on this report till 31 August 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Global Acute Ischemic Stroke Therapeutics Market 2017-2021

Table of Contents

PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
Market outline
PART 05: Acute ischemic stroke (AIS): An overview
Ischemia
IHD
Stroke
AIS
PART 06: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 07: Pipeline landscape
PART 08: Market segmentation by drug-class
Thrombolytic therapeutics
Antihypertensive therapeutics
Antiplatelet therapeutics
Anticoagulants
Others
PART 09: Geographical segmentation
Market overview based on geography
AIS therapeutics market in Americas
AIS therapeutics market in EMEA
AIS therapeutics market in APAC
PART 10: Decision framework
PART 11: Drivers and challenges
Market drivers
Market challenges
PART 12: Market trends
TBI, a value-addition in AIS research
Advent of genomic medicine
PART 13: Vendor landscape
Competitive scenario
Key news
PART 14: Key vendor analysis
Bayer
Boehringer Ingelheim
F. Hoffmann-La Roche
Sanofi
Other prominent vendors
PART 15: Appendix
List of abbreviations

List of Exhibits
Exhibit 01: Symptoms of AIS
Exhibit 02: Global AIS therapeutics market: Snapshot
Exhibit 03: Global AIS therapeutics market 2016-2021 ($ millions)
Exhibit 04: Mechanism of action of alteplase
Exhibit 05: Global AIS therapeutics market: Opportunity analysis
Exhibit 06: Five forces analysis
Exhibit 07: Pipeline snapshot
Exhibit 08: Key clinical trials
Exhibit 09: Global AIS therapeutics market segmentation by drug-class
Exhibit 10: Global AIS therapeutics market share by drug-class 2016
Exhibit 11: Global AIS thrombolytic therapeutics market 2016-2021 ($ millions)
Exhibit 12: Global AIS antihypertensive therapeutics market 2016-2021 ($ millions)
Exhibit 13: Global AIS antiplatelet therapeutics market 2016-2021 ($ millions)
Exhibit 14: Global AIS anticoagulant therapeutics market 2016-2021 ($ millions)
Exhibit 15: Global AIS therapeutics market share by geography 2016 and 2021
Exhibit 16: Global AIS therapeutics market by geography 2016-2021 ($ millions)
Exhibit 17: Global AIS therapeutics market by geography 2016-2021 (% share)
Exhibit 18: AIS therapeutics market scenario in different geographies
Exhibit 19: Market scenario in Americas
Exhibit 20: Stroke scenario in US: An overview
Exhibit 21: AIS therapeutics market in Americas 2016-2021 ($ millions)
Exhibit 22: Market scenario in EMEA
Exhibit 23: AIS therapeutics market in EMEA 2016-2021 ($ millions)
Exhibit 24: Market scenario in APAC
Exhibit 25: AIS therapeutics market in APAC 2016-2021 ($ millions)
Exhibit 26: Prevalence of stroke in US
Exhibit 27: ACTIVASE regional sales 2015 and 2016
Exhibit 28: Prevalence of obesity among US adults in 2015
Exhibit 29: Competitive structure analysis of global AIS therapeutics market 2016
Exhibit 30: Bayer: Key highlights
Exhibit 31: Bayer: Strength assessment
Exhibit 32: Bayer: Strategy assessment
Exhibit 33: Bayer: Opportunity assessment
Exhibit 34: Boehringer Ingelheim: Key highlights
Exhibit 35: Boehringer Ingelheim: Strength assessment
Exhibit 36: Boehringer Ingelheim: Strategy assessment
Exhibit 37: Boehringer Ingelheim: Opportunity assessment
Exhibit 38: F. Hoffmann-La Roche: Key highlights
Exhibit 39: F. Hoffmann-La Roche: Strength assessment
Exhibit 40: F. Hoffmann-La Roche: Strategy assessment
Exhibit 41: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 42: Sanofi: Key highlights
Exhibit 43: Sanofi: Strength assessment
Exhibit 44: Sanofi: Strategy assessment
Exhibit 45: Sanofi: Opportunity assessment
  • United States Peptide Therapeutics Market Report 2017
    Published: 18-Aug-2017        Price: US 3800 Onwards        Pages: 98
    In this report, the United States Peptide Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rat......
  • United States Hypertrophic Cardiomyopathy Therapeutics Market Report 2017
    Published: 17-Aug-2017        Price: US 3800 Onwards        Pages: 102
    In this report, the United States Hypertrophic Cardiomyopathy Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market ......
  • Raynauds Disease - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 48
    Raynauds Disease - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Raynauds Disease - Pipeline Review, H2 2017, provides an overview of the Raynauds Disease (Cardiovascular) pipeline landscape. Raynauds disease is a common condition that affects the blood supply to certain parts of the body, usually the fingers and toes. Predisposing factors include age, gender, family history and smok......
  • Batten Disease - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 53
    Batten Disease - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Batten Disease - Pipeline Review, H2 2017, provides an overview of the Batten Disease (Central Nervous System) pipeline landscape. Batten disease, a rare genetic disorder, belongs to a group of progressive degenerative neurometabolic disorders known as the neuronal ceroid lipofuscinoses. Symptoms of Batten disease usually......
  • Trigeminal Neuralgia - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 54
    Trigeminal Neuralgia - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Trigeminal Neuralgia - Pipeline Review, H2 2017, provides an overview of the Trigeminal Neuralgia (Central Nervous System) pipeline landscape. Trigeminal neuralgia is a chronic pain condition that affects the trigeminal nerve, which carries sensation from face to brain. Symptoms include spontaneous attacks of pain o......
  • Visceral Pain - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 55
    Visceral Pain - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Visceral Pain - Pipeline Review, H2 2017, provides an overview of the Visceral Pain (Central Nervous System) pipeline landscape. Visceral pain is a type of nociceptive pain that comes from the internal organs. Symptoms include aches, cramps and diffuse pain. Treatment includes analgesics such as narcotics or NSAIDs and pai......
  • Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 119
    Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2017, provides an overview of the Spinal Muscular Atrophy (SMA) (Central Nervous System) pipeline landscape. Spinal muscular atrophy (SMA) is a genetic disease that attacks nerve cells, called motor neurons, in the spinal cord. These critically important c......
  • Liver Cirrhosis - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 90
    Liver Cirrhosis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Cirrhosis - Pipeline Review, H2 2017, provides an overview of the Liver Cirrhosis (Gastrointestinal) pipeline landscape. Cirrhosis is scarring of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcohol abuse. The scar tissue damages the normal structure of the liver wh......
  • Global Peptide Therapeutics Sales Market Report 2017
    Published: 14-Aug-2017        Price: US 4000 Onwards        Pages: 101
    In this report, the global Peptide Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Peptide Therapeutics for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs